Source: International Congress 2017 – Paediatric TB: MDRTB (II)
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
L. Chen (Sydney, NSW, Australia). Clinical management improves the treatment outcome of MDR-TB patients. 2765

Member's Comments

No comment yet.

Related content which might interest you: Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 MDR/XDR-TB treatment outcome Source: Annual Congress 2009 - Treatment of tuberculosis at times of emerging drug resistance Year: 2009 Impact of XDR-TB on treatment outcome of MDR-TB patients with standardized regimens Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008 Clinical characteristics and treatment outcomes of tuberculosis in the elderly Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings Year: 2012 Clinical characteristics and treatment outcomes of patients with pulmonary tuberculosis with delayed conversion over 4 months Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Long-term effectiveness of surgery treatment of TB patients Source: Virtual Congress 2020 – Tuberculosis and adverse events in different populations Year: 2020 Tuberculosis in the very elderly – clinical presentation and treatment outcomes Source: International Congress 2018 – Tuberculosis comorbidities Year: 2018 Treatment effectiveness and predictors of poor outcome in MDR-TB and XDR-TB Source: Breathe 2008; 6: 161 Year: 2009 Early outcomes in MDR-TB and XDR-TB patients treated with delamanid under compassionate use Source: Eur Respir J, 50 (1) 1700311; 10.1183/13993003.00311-2017 Year: 2017 Treatment interruptions in patients with MDR/XDR-TB: risk factors and impact on treatment outcomes Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Influence of statin therapy on clinical symptoms, severity and prognosis in patients with community acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 Time to sputum culture conversion as a prognostic marker for end-of-treatment outcome in the first cohorts of MDR-TB patients managed in a Nigerian tertiary hospital Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Medical thoracoscopy (MT): A safe and effective strategy in the diagnosis and treatment of patients presenting life threatening comorbidities. Association with clinical outcome Source: Annual Congress 2010 - 100 years of thoracoscopy: still room for improvement? Year: 2010 Early experience with the implementation of the WHO shorter MDR-TB treatment regimen in Singapore Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Clinical efficacy of new anti-TB drug ²tubelon² during complex chemotherapy in patients with first-time diagnosed destuctive pulmonary TB Source: Eur Respir J 2006; 28: Suppl. 50, 8s Year: 2006 Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Treatment outcomes for XDR TB patients with surgery Source: Annual Congress 2007 - Multidrug-resistant tuberculosis and the emerging threat of extensively drug-resistant tuberculosis Year: 2007 Does clinical score evaluation improve management in bronchiolitis patients? Source: Eur Respir J 2007; 30: Suppl. 51, 391s Year: 2007